All In Biotech

Drug Trial Radar · NCT01547091

Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis

Clinical Trial of Umbilical Cord-Derived Mesenchymal Stem Cells Transplantation for Rheumatoid Arthritis-Phase I/II

Last checked: Nov 19, 2026Latest source record: Jun 27, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Apr 2013

Primary completion

Oct 2014

Study completion Dec 2014

Sponsor

Sponsor type
Industry
First posted
Mar 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rheumatoid arthritis is a chronic systemic disease, which is characterized by chronic inflammation in the synovial tissue. Rheumatoid arthritis will eventually result in the destruction of cartilage, bone and ligaments and joint deformity. The underlying hypothesis is that umbilical cord-derived mesenchymal stem cell (UC-MSCs) has anti-inflammatory effects and thus potentially alleviates the progression of rheumatoid arthritis. The study is to explore the safety and efficacy of UC-MSCs transplantation in treatment of rheumatoid arthritis.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)Biological

    -The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.

  • Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)Drug

    -Patients will be treated by conventional drugs (DMARDS) for alleviating disease.

  • UC-MSC+DMARDSBiological

    The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of MSC treatment.Time frame: six months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The 323 Hospital of Chinese People's Liberation Army

    Xi'an, Shaanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.